Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 8

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 8
---
  regulatory authorities may identify deficiencies in manufacturing processes;  
 ────────────────────────────────────────────────────────────────────────────────

  regulatory authorities may change their approval policies or adopt new regulations;  
 ───────────────────────────────────────────────────────────────────────────────────────

  the third party manufacturers we expect to depend on to supply or manufacture our drug candidates may not produce adequate supply;  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  we, or our third party manufacturers, may not be able to source or produce current Good Manufacturing Practice (cGMP) materials for the production of our drug candidates;  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  we may not be able to manufacture our drug candidates at a cost or in quantities necessary to make commercially successful products;  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  we may not be able to obtain adequate supply of our drug candidates for our clinical trials;  
 ────────────────────────────────────────────────────────────────────────────────────────────────

  we may experience delays in the commencement of, enrolment of patients in and timing of our clinical trials;  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  we may not be able to demonstrate that our drug candidates are safe and effective as a treatment for its indications to the satisfaction of regulatory authorities, and we may not be able to ach...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  we may not be able to maintain a continued acceptable safety profile of our products following approval;  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────

  we may be unable to establish or maintain collaborations, licensing or other arrangements;  
 ──────────────────────────────────────────────────────────────────────────────────────────────

  the market may not accept our drug candidates;  
 ──────────────────────────────────────────────────

  we may be unable to establish and maintain an effective sales and marketing infrastructure, either through the creation of a commercial infrastructure or through strategic collaborations, and t...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────